Form 4 Filing for Spyre Therapeutics, Inc.

On May 1, 2026, Turtle Cameron, Chief Executive Officer and Director of Spyre Therapeutics, Inc. (SYRE), reported the sale of various non-derivative securities. The transactions, executed under a Rule 10b5-1 trading plan adopted on June 20, 2025, involved the sale of a total of 14,900 shares of Common Stock. These sales were conducted at weighted average prices ranging from $69.54 to $74.96 per share. Following these transactions, Mr. Cameron directly holds 612,540 shares of Common Stock. It is important to note that 101,653 of these shares are subject to vesting conditions through November 2026. The filing details the specific number of shares sold at each price point within the reported ranges, with the undertaking to provide further information upon request.